Elana Rosenthal

Elana Rosenthal

Auto-generated profile, based on publicly available information

Elana Rosenthal

Division of Clinical Care and Research, Institute of Human Virology at the University of Maryland School of Medicine , Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in The American Journal of Medicine
Verified
Journal Article
Closed access
ERElana S. Rosenthal
Elana S. Rosenthal
AKAdolf W. Karchmer
Adolf W. Karchmer
JTJesse Theisen-Toupal
Jesse Theisen-Toupal
RCRoger Araujo Castillo
Roger Araujo Castillo
CRChris F. Rowley
Chris F. Rowley

5 September 2017 in Annals of Internal Medicine
Verified
Journal Article
Closed access
SKSarah Kattakuzhy
Sarah Kattakuzhy
CGChloe Gross
Chloe Gross
BEBenjamin Emmanuel
Benjamin Emmanuel
GTGebeyehu Teferi
Gebeyehu Teferi
VJVeronica Jenkins
Veronica Jenkins
TPThe Ascend Providers
The Ascend Providers
The number of patients with hepatitis C virus infection who would benefit from direct-acting antiviral therapy greatly exceeds the current workforce capacity of specialists in infectious disease an... Background: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection has resulted in high rates of disease cure; however, not enough specialists currently are available to provid...

23 October 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ERElana S Rosenthal
Elana S Rosenthal
RSRachel Silk
Rachel Silk
PMPoonam Mathur
Poonam Mathur
CGChloe Gross
Chloe Gross
RERahwa Eyasu
Rahwa Eyasu
SKSarah Kattakuzhy
Sarah Kattakuzhy
People who inject drugs have a high prevalence of hepatitis C virus (HCV) and significant disease associated with drug use; however, HCV treatment often occurs in absence of interventions to address opioid use disorder and drug use–related harms. The impact of concurrent initiation of opioid agonist therapy (OAT) on HCV treatment and drug use outcomes is unknown. In this prospective, open-label, observational trial at a harm reduction organization’s drop-in center in Washington, DC, 100 patients with chronic HCV infection, opioid use disorder, and ongoing injection drug use were treated with sofosbuvir-velpatasvir for 12-weeks and offered buprenorphine initiation. The primary end point was sustained virologic response (SVR), and secondary end points included uptake of and retention in OAT, change in risk behavior, and determinants of SVR. Eighty-two patients (82%) achieved SVR, which was not associated with baseline OAT status (P = .33), on-treatment drug use (P >.99), or imperfect daily adherence (P = .35) but was significantly associated with completing 2 or more 28-pill bottles of sofosbuvir-velpatasvir (P < .001) and receiving OAT at week 24 (P = .01). Of 67 patients not already receiving OAT at baseline, 53 (79%) started OAT. At week 24, 68 (68%) patients were receiving OAT. Receipt of OAT was associated with fewer opiate-positive urine drug screens (P = .003), lower human immunodeficiency virus risk-taking behavior scores (P < .001), and lower rates of opioid overdose (P = .04). The Novel Model of Hepatitis C Treatment as an Anchor to Prevent HIV, Initiate Opioid Agonist Therapy, and Reduce Risky Behavior study demonstrates high uptake of buprenorphine collocated with HCV treatment, and it shows that concurrent initiation of OAT with HCV treatment can result in high rates of SVR while reducing risks associated with drug use. NCT03221309.

16 May 2016 in Infectious Agents and Cancer
Verified
Journal Article
Open access
PDF file
ERElana S. Rosenthal
Elana S. Rosenthal
CGCamilla Graham
Camilla Graham
Hepatitis C virus is a serious infection causing cirrhosis, liver cancer, and death. The recent development of direct-acting antivirals has dramatically improved tolerability of treatment and rates of cure. However, the high price of these medications has often limited access to care and resulted in rationing of medications in the United States to those with advanced liver disease, access to specialist care, and without active substance use. This review assesses the way pharmaceutical prices are established and how pricing of directly acting antiviral regimens in the United States has impacted access to treatment for hepatitis C virus.

4 April 2019 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
TSTara A Schwetz
Tara A Schwetz
TCThomas Calder
Thomas Calder
ERElana Rosenthal
Elana Rosenthal
SKSarah Kattakuzhy
Sarah Kattakuzhy
AFAnthony S Fauci
Anthony S Fauci
A converging public health crisis is emerging because the opioid epidemic is fueling a surge in infectious diseases, such as human immunodeficiency virus infection with or without AIDS, the viral hepatitides, infective endocarditis, and skin and soft-tissue infections. An integrated strategy is needed to tailor preventive and therapeutic approaches toward infectious diseases in people who misuse and/or are addicted to opioids and to concurrently address the underlying predisposing factor for the infections—opioid use disorder. This commentary highlights the unique and complementary roles that the infectious diseases and substance use disorder communities can play in addressing this crisis of dual public health concerns.

1 March 2019 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
PLP Alexander Leahey
P Alexander Leahey
MLMary T LaSalvia
Mary T LaSalvia
ERElana S Rosenthal
Elana S Rosenthal
AKAdolf W Karchmer
Adolf W Karchmer
CRChristopher F Rowley
Christopher F Rowley
Hospitalizations for individuals with injection drug use-related infective endocarditis (IDU-IE) represent an increasing portion of all patients with endocarditis. This study describes the evolving trends in demographics, clinical characteristics, rates of surgical intervention, and mortality among patients hospitalized with IE, comparing those with and without injection drug use. This is a retrospective cohort study of patients admitted between January 1, 2007 to June 30, 2015 at a tertiary care center in Boston, Massachusetts. Endocarditis was defined by International Classification of Diseases, Ninth Revision code and verified by the modified Duke Criteria for IE. The clinical characteristics, microbiology, site of infection, complications of IE, and outcome were all abstracted by chart review. Rates of surgical consultation and surgical intervention within 90 days of admission were obtained, and assessment of surgical risk calculated was by EuroSCORE II (euroscore.org/calc). Subsequent hospitalizations for all causes were also reviewed. Injection drug use-related infective endocarditis occurred in younger patients with lower rates of diabetes, renal dysfunction, and prior cardiothoracic (CT) surgery than those without IDU. Injection drug use-related infective endocarditis was associated with higher rates of complications, CT surgery consultation, and surgery within 90 days for absolute surgical indication. Readmissions for endocarditis occurred in 20% of IDU-IE patients and 9% of those with non-IDU IE. All-cause 1-year mortality rates were similar (IDU-IE 16%, non-IDU IE 13%; P = .58). Despite younger age, fewer medical comorbidities, and fewer prior cardiac surgeries, all-cause 1-year mortality was similar for patients after sentinel admission for IDU-IE compared with non-IDU IE. Interventions in the acute hospital setting and after discharge are needed to support patients with IDU-IE, focusing on harm reduction and treatment of addiction to reduce the unexpectedly high mortality of this young population.